Policy document review · October 29, 2026
Policy note · October 29, 2026 October 29: The draft HHS policy describes conditional 503A compounding discretion for specified forms and routes, not 503B access or product approval. For each peptide, discretion lasts until a final rule decides 503A-list inclusion or exclusion.
The policy note is separate from this library's clinical records. Their existing evidence dates and approval classifications have not been refreshed by this update.
Read the dated document update ↗ The evidence reference
A name is a start.Examine the evidence. Explore eleven peptide profiles, then follow the sources behind each claim. Search by name, browse a body system or narrow the list by regulatory status.
Name or alias Regulatory statusAll statuses Approved product Investigational Not FDA-approved Topical cosmetic Clear filters
Browse by system All systems11 Metabolism6 Skin1 Hormones2 Sexual health1 Muscles and joints1
These categories organize the library. The diagram is a navigation aid, not a map of proven benefits.
Read the scope behind the label
Approved product A specific product has an FDA-approved use; read the scope in its entry.
Investigational A research candidate without the approved product described in this library.
Not FDA-approved No approved product is established by the official records reviewed.
Topical cosmetic The entry concerns topical cosmetic use, not a treatment indication. A trial tests a question. Approval is a separate regulatory decision for a specific product and use.
An educational reference from the Comparison Desk. AI-assisted; not reviewed by a licensed clinician. This library does not provide prescriptions or instructions for self-treatment.